Second primary malignancies in multiple myeloma: A review
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
As survival times of multiple myeloma (MM) patients continue to improve, second primary malignancies (SPM) have become an increasingly relevant long-term risk among MM survivors. Population studies since the 1960s have consistently observed an increased incidence of hematologic SPMs, specifically acute leukemia, among MM survivors. Prolonged treatment with alkylators, especially melphalan, was associated with an increased hematologic SPM risk, likewise autologous stem cell transplantation appeared to minimally increase SPM risk. Immunomodulatory drugs, specifically lenalidomide, was associated with an increased SPM incidence, although most studies concluded that the benefits of therapy outweighed any risk of SPMs. Newer anti-myeloma therapy such as proteasome inhibitors and monoclonal antibodies did not appear to increase SPM risk although robust long-term follow-up is lacking. This review discusses current understanding regarding SPM among survivors of MM, how different host-, disease- and treatment-related factors contribute to SPM incidence and highlights emerging screening guidelines and prognosis for SPMs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Age-related clonal hematopoiesis associated with adverse outcomes
Jaiswal, S., Fontanillas, P., Flannick, J., Manning, A., Grauman, P. V., Mar, B. G., Lindsley, R. C., Mermel, C. H., Burtt, N., Chavez, A., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1408617 · Cited by 4,841
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Dimopoulos, M. A., Oriol, A., Nahi, H., San-Miguel, J., Bahlis, N. J., Usmani, S. Z., Rabin, N., Orlowski, R. Z., Komarnicki, M., Suzuki, K., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607751 · Cited by 1,445 · cited 1×
“In addition, 10 out of 18 patients with SPMs had noninvasive, continuous SPM such as squamous cell carcinoma or basal cell carcinoma suggesting no increased risk of SPM with the addition of daratumumab [42].”
BackgroundCarfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma
Stewart, A. K., Rajkumar, S. V., Dimopoulos, M. A., Masszi, T., Špička, I., Oriol, A., Hájek, R., Rosiñol, L., Siegel, D. S., Mihaylov, G. G., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411321 · Cited by 1,332
Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma
Attal, M., Lauwers-Cances, V., Marit, G., Caillot, D., Moreau, P., Facon, T., Stoppa, A. M., Hulin, C., Benboubker, L., Garderet, L., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1114138 · Cited by 1,155 · cited 2×
“The increased SPM risk was observed to be so significant in this setting that the IFM 2005-02 study was prematurely stopped due to concerns regarding high SPM rates at a median time of 2 years [47], while the CALGB study completed accrual.”
BackgroundLenalidomide after Stem-Cell Transplantation for Multiple Myeloma
McCarthy, P. L., Owzar, K., Hofmeister, C. C., Hurd, D. D., Hassoun, H., Richardson, P. G., Giralt, S., Stadtmauer, E. A., Weisdorf, D. J., Vij, R., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1114083 · Cited by 1,147 · cited 1×
“9% with placebo after a median follow-up time of 91 months [46, 51].”
Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
Moreau, P., Masszi, T., Grzasko, N., Bahlis, N. J., Hansson, M., Pour, L., Sandhu, I., Ganly, P., Baker, B. W., Jackson, S. R., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1516282 · Cited by 1,060 · cited 1×
“The TOURMALINE-MM1 trial which randomized 722 patients with relapsed/refractory MM to Ixazomib with lenalidomide and dexamethasone or placebo plus lenalidomide and dexamethasone showed no difference in SPM incidence between the two groups.[59] Similarly, the MM3 trial which randomized MM patients who had achieved at l…”
McCarthy, P. L., Holstein, S. A., Petrucci, M. T., Richardson, P. G., Hulin, C., Tosi, P., Bringhen, S., Musto, P., Anderson, K. C., Caillot, D., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.72.6679 · Cited by 698
Facon, T., Dimopoulos, M. A., Dispenzieri, A., Catalano, J. V., Belch, A., Cavo, M., Pinto, A., Weisel, K., Ludwig, H., Bahlis, N. J., et al. (2018) · Blood · doi:10.1182/blood-2017-07-795047 · Cited by 271
Goldschmidt, H., Lokhorst, H. M., Mai, E. K., van der Holt, B., Blau, I. W., Zweegman, S., Weisel, K. C., Vellenga, E., Pfreundschuh, M., Kersten, M. J., et al. (2018) · Leukemia · doi:10.1038/leu.2017.211 · Cited by 200
Cited by
Martin, T., Usmani, S. Z., Berdeja, J. G., Agha, M., Cohen, A. D., Hari, P., Avigan, D., Deol, A., Htut, M., Lesokhin, A., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.00842 · Cited by 663
Ailawadhi, S., Arnulf, B., Patel, K., Cavo, M., Nooka, A. K., Manier, S., Callander, N., Costa, L. J., Vij, R., Bahlis, N. J., et al. (2024) · Blood · doi:10.1182/blood.2024024582 · Cited by 79
Inhibition of acetylation, is it enough to fight cancer?
López-Bañuelos, L., & Vega, L. (2022) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2022.103752 · Cited by 32
Kiss, S., Gede, N., Hegyi, P., Nagy, B., Deák, R., Dembrovszky, F., Bunduc, S., Erőss, B., Leiner, T., Szakács, Z., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-01440-x · Cited by 23
Metadata
- Authors
- Poh, C., Keegan, T., & Rosenberg, A. S.
- Venue
- Blood Reviews
- Publisher
- Elsevier BV
- Published
- 2021-03
- Volume
- 46
- Pages
- 100757
- ISSN
- 0268-960X (ISSN-L)
- OpenAlex
- W3083741488
- Cited by
- 73
- References
- 9
- FWCI
- 5.22
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Second primary malignancies in multiple myeloma: A review. https://app.cochat.ai/papers/10.1016/j.blre.2020.100757
- The paper
- Poh, C., Keegan, T., & Rosenberg, A. S. (2021). Second primary malignancies in multiple myeloma: A review. Blood Reviews. https://doi.org/10.1016/j.blre.2020.100757
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.